Equities
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,950.00
  • Today's Change55.00 / 1.12%
  • Shares traded4.96m
  • 1 Year change+22.07%
  • Beta1.2474
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 18-Sep-24
Select bar for recommendation details.
Recommendations18-Sep-24
Buy6
Outperform10
Hold1
Sell0
Strong Sell0

Share price forecast in JPY

The 15 analysts offering 12 month price targets for Daiichi Sankyo Co Ltd have a median target of 6,550.00, with a high estimate of 7,600.00 and a low estimate of 5,700.00. The median estimate represents a 32.32% increase from the last price of 4,950.00.
High53.5%7,600.00
Med32.3%6,550.00
Low15.2%5,700.00

Dividends in JPY

In 2024, Daiichi Sankyo Co Ltd reported a dividend of 50.00 JPY, which represents a 66.67% increase over last year. The 14 analysts covering the company expect dividends of 58.20 JPY for the upcoming fiscal year, an increase of 16.40%.
Div growth (TTM)66.67%
More ▼

Earnings history & estimates in JPY

On Jul 31, 2024, Daiichi Sankyo Co Ltd reported 1st quarter 2025 earnings of 44.60 per share. This result exceeded the 23.30 consensus of the 5 analysts covering the company and exceeded last year's 1st quarter results by 49.97%.
The next earnings announcement is expected on Oct 28, 2024.
Average growth rate+30.65%
Daiichi Sankyo Co Ltd reported annual 2024 earnings of 104.69 per share on Apr 25, 2024.
Average growth rate+23.75%
More ▼

Revenue history & estimates in JPY

Daiichi Sankyo Company, Limited had 1st quarter 2025 revenues of 436.18m. This bettered the 407.29m consensus of the 5 analysts covering the company. This was 24.32% above the prior year's 1st quarter results.
Average growth rate+5.93%
Daiichi Sankyo Company, Limited had revenues for the full year 2024 of 1.60bn. This was 25.28% above the prior year's results.
Average growth rate+13.56%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.